Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation
Status:
Not yet recruiting
Trial end date:
2021-11-20
Target enrollment:
Participant gender:
Summary
At present, with the increasing intensities of the tobacco industry and air pollution in
China, the incidence and mortality of lung cancer have become the most important issue that
threatens human health.Over the past two decades, the treatment of EGFR+ NSCLC is molecular
target therapy (EGFR-TKI). However, only about 30 percent patients with T790M mutation could
accept 3rd generation of EGFR-TKI（AZD9291) , most of the patients with progressive disease
statuses still stays in the mode of treatment based on radiotherapy and chemotherapy. This is
a prospective, single-center, one-arm clinical study designed to evaluate the efficacy and
safety of apatinib plus chemotherapy for 30 patients who progressed after EGFR-TKI treatment
without T790M mutation. The participants will receive apatinib 250mg qd orally combine with
chemotherapy, if the patient has a grade 3/4 adverse reaction during such treatment, it can
be reduced to apatinib 250mg orally once per two days. Chemotherapeutic agents are limited to
platinum-based double drugs chemotherapy.The primary outcome endpoint was progression-free
survival.
Phase:
Phase 2
Details
Lead Sponsor:
First Hospital of Jilin University The First Hospital of Jilin University